Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.40 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642427 | 1.00 | F2 (0.44) | F2DPP4CHRM2CHRM4CHRM5 | |
| SCHEMBL606217 | 1.00 | F2 (0.44) | F2DPP4CHRM2CHRM4CHRM5 | |
| SCHEMBL642472 | 0.94 | CHRM2 (0.42) | F2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17327535 | 0.94 | CHRM2 (0.42) | F2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL641124 | 0.92 | CHRM2 (0.44) | F2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL4721124 | 0.87 | SMN1; SMN2 (0.36) | F2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL14621092 | 0.84 | F2 (0.42) | F2CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL21102001 | 0.84 | DPP4 (0.39) | F2DPP4 | |
| SCHEMBL13435754 | 0.84 | DPP4 (0.39) | DPP4 | |
| Benzoic Acid SCHEMBL9530741 | 0.83 | DPP4 (0.53) | F2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022106630-A1 | STABLE FORMULATIONS COMPRISING PIPERACILLIN AND/OR TAZOBACTAM | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| WO-2022106611-A1 | NOVEL COMPOSITIONS OF BETA-LACTAM COMPOUNDS | XELLIA PHARMACEUTICALS APS (DK) | 2022-05-27 | — | — | WO | claimed |
| EP-1660507-B2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | MILLENNIUM PHARM INC (US) | 2017-01-04 | — | — | EP | claimed |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | CEPHALON, INC. (US) | 2011-06-16 | — | — | US | claimed |
| US-7915236-B2 | Proteasome inhibitors and methods of using the same | CEPHALON, INC. (US) | 2011-03-29 | — | — | US | claimed |
| US-RE41339-E1 | N-acetyl aldosamines, N-acetylamino acids and related N-acetyl compounds and their topical use | TRISTRATA, INC. (US) | 2010-05-18 | — | — | US | claimed |
| US-RE41278-E1 | N-acetyl aldosamines and related N-acetyl compounds, and their topical use | TRISTRATA, INC. | 2010-04-27 | — | — | US | claimed |
| EP-1660507-B9 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2010-03-24 | — | — | EP | claimed |
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2009-11-26 | — | — | US | claimed |
| EP-1660507-B1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON INC (US) | 2009-08-05 | — | — | EP | claimed |
| US-20060063827-A1 | Systemic administration of therapeutic amino acids and N-acetylamino acids | YU RUEY J | 2006-03-23 | — | — | US | claimed |
| EP-1601366-A1 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | Yu, Ruey J., Dr. (US) | 2005-12-07 | — | — | EP | claimed |
| US-20050196418-A1 | Bioavailability and improved delivery of alkaline pharmaceutical drugs | YU RUEY J (US) | 2005-09-08 | — | — | US | claimed |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-05-19 | — | — | US | claimed |
| WO-2005021558-A2 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | CEPHALON, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| US-20040220264-A1 | Bioavailability and improved delivery of acidic pharmaceutical drugs | YU RUEY J | 2004-11-04 | — | — | US | claimed |
| US-20040214215-A1 | Bioavailability and improved delivery of alkaline pharmaceutical drugs | YU RUEY J (US) | 2004-10-28 | — | — | US | claimed |
| WO-2004080468-A1 | IMPROVED BIOAVAILABILITY AND IMPROVED DELIVERY OF ALKALINE PHARMACEUTICAL DRUGS | YU RUEY J (US) | 2004-09-23 | — | — | WO | claimed |
| US-20040147452-A1 | Non-amphoteric glutathione derivative compositions for tropical application | YU RUEY J | 2004-07-29 | — | — | US | claimed |
| WO-2004010968-A1 | NON-AMPHOTERIC GLUTATHIONE DERIVATIVE COMPOSITIONS FOR TOPICAL APPLICATION | YU RUEY J (US) | 2004-02-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291918-A1 | PROTEASOME INHIBITORS AND METHODS OF USING THE SAME | PSMB11, PSMB5, PSMB6 | F2 4871/4885DPP4 1393/4885CHRM2 4879/4885 |
| US-20050107307-A1 | Proteasome inhibitors and methods of using the same | PSMB11, PSMB5, PSMB6 | F2 4871/4885DPP4 1393/4885CHRM2 4879/4885 |
| US-20110144033-A1 | Proteasome Inhibitors and Methods of Using the Same | PSMB11, PSMB5, PSMB6 | F2 4871/4885DPP4 1393/4885CHRM2 4879/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.